Philip Tsai Purchases 10,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average cost of $20.49 per share, with a total value of $204,900.00. Following the completion of the acquisition, the insider owned 43,300 shares of the company’s stock, valued at approximately $887,217. This trade represents a 30.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immunome Stock Performance

Shares of IMNM opened at $21.44 on Monday. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $25.30. The stock has a market capitalization of $1.97 billion, a P/E ratio of -7.27 and a beta of 2.17. The company’s fifty day moving average is $17.68 and its two-hundred day moving average is $12.73.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. Sell-side analysts predict that Immunome, Inc. will post -2.21 EPS for the current year.

Wall Street Analysts Forecast Growth

IMNM has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $21.00 price objective on shares of Immunome in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Leerink Partners set a $40.00 price objective on shares of Immunome in a research note on Monday, December 15th. Finally, Truist Financial initiated coverage on shares of Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.09.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Assetmark Inc. purchased a new position in shares of Immunome during the 3rd quarter worth $39,000. BNP Paribas Financial Markets lifted its holdings in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the period. Tower Research Capital LLC TRC increased its position in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the last quarter. BIT Capital GmbH purchased a new stake in shares of Immunome during the 3rd quarter valued at $69,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Immunome during the 3rd quarter worth $76,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.